1 Min Read
LONDON, Oct 29 (Reuters) - AstraZeneca PLC : * Begins a new global study of Faslodex (fulvestrant) 500 mg injection in
patients with hormone receptor-positive advanced breast cancer
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.